CDH2 and leukemia: 92). Although ADH-1 has been documented in cancer pre-clinical studies and solid tumour clinical trials, in-depth mechanism of action of this drug remains unexplored. Further research needs to be conducted to develop an in-depth understanding of ADH-1, including scrutiny of any possible mechanisms of resistance that could arise following ADH-1 treatment. In addition, several next-generation antagonists, including small-molecule inhibitors of CDH2 are being developed (Ref. 38) and their role as potential anti-leukaemia treatment needs to be investigated.